Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Fresenius Medical Care AG & Co. KGaA (FMS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
25.11+0.17 (+0.68%)
At close: 04:00PM EDT
25.11 0.00 (0.00%)
After hours: 04:04PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close24.94
Open24.54
Bid22.80 x 800
Ask25.09 x 1100
Day's Range24.52 - 25.11
52 Week Range23.29 - 42.13
Volume382,389
Avg. Volume565,487
Market Cap14.716B
Beta (5Y Monthly)0.94
PE Ratio (TTM)15.79
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.71 (2.82%)
Ex-Dividend DateMay 13, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
21% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for FMS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Fresenius Medical Care AG
    Analyst Report: Fresenius Medical Care AG & Co. KGaAFresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of September 2021. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.
    Rating
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • Reuters

    UPDATE 1-U.S. Supreme Court rules against DaVita over dialysis coverage

    The U.S. Supreme Court on Tuesday rejected dialysis provider DaVita Inc's claims that an Ohio hospital's employee health plan discriminates against patients with end-stage kidney disease by reimbursing them at low rates in hopes they would switch to Medicare. In a 7-2 decision https://fingfx.thomsonreuters.com/gfx/legaldocs/byvrjaqorve/06212022davita.pdf authored by conservative Justice Brett Kavanaugh, the court ruled that Marietta Memorial Hospital's employee health plan did not violate federal law by limiting benefits for outpatient dialysis because it did so without regard to whether patients had end-stage renal disease.

  • Zacks

    Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

    Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

  • Zacks

    Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates

    Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.

Advertisement
Advertisement